As the Project Head at AstraZeneca, Bob was behind the discovery and early clinical progression of the anti-thrombotic (P2Y12 antagonists) compounds Brilinta (ticagrelor) and Kengreal (cangrelor). He has co-founded several consultancy companies including Adhale, VisionRealisation Ltd, and TherapeutAix UG. He also acts as a Scientific Advisor to a number of life sciences companies and academic groups. Bob co-founded Platelet Services, acting as the Non-Executive Director and Drug Discovery Advisor bringing his expertise in platelet research, translational science, discovery project optimisation and de-risking.